Thus, in the case of CR-expressing mesothelial and mesothelioma cells, CR or more precisely its down-regulation, might be viewed as a potential new target/strategy for malignant mesothelioma therapy (Blum and Schwaller, 2013). This evidence concerns the gene CALB2 and mesothelioma.